Scilex Holding Company

SCLX Healthcare Drug Manufacturers General

Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.

2.83 0.01 +0.35%
Market cap
$19.8M
P/E
0.0×
Fwd P/E
−7.5×
Dividend yield
—
F-score
3/9
Altman Z
−7.96
Beneish M
−7.77
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
3.52 2.77 0.84 1.70
P/FCF ratio
5.97 22.96 0.00 0.00
P/Operating CF
17.27 (4.80) (25.83) (7.98)
P/B ratio
0.00 0.00 0.00 0.00
EV/Sales
4.65 5.19 3.16 4.27
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
7.89 42.97 (30.88) (7.57)
Current Ratio
0.05 0.08 0.08 0.07
Net Debt/EBITDA
(0.24) (2.02) (2.74) (3.13)
Debt/Equity
(0.25) (0.39) (0.32) (0.26)
Earnings Yield
(183.73%) (479.61%) (975.18%) (637.18%)
Free Cash Flow Yield
16.74% 4.36% (12.10%) (33.15%)
Free Cash Flow per Share
0.71 (1.60) (0.58) (1.06)
Book value per Share
(15.49) (19.19) (36.87) (45.05)
Free Cash Flow
8.23 (17.60) (4.01) (7.31)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates